InspireMD Dirección

Dirección controles de criterios 1/4

El CEO de InspireMD's es Marvin Slosman , nombrado en Jan 2020, tiene una permanencia de 4.42 años. compensación anual total es $3.22M, compuesta por 14.6% salario y 85.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.026% de las acciones de la empresa, por valor de €16.29K. La antigüedad media del equipo directivo y de la junta directiva es de 0.8 años y 7.8 años, respectivamente.

Información clave

Marvin Slosman

Chief Executive Officer (CEO)

US$3.2m

Compensación total

Porcentaje del salario del CEO	14.6%
Permanencia del CEO	4.8yrs
Participación del CEO	0.02%
Permanencia media de la dirección	1.1yrs
Promedio de permanencia en la Junta Directiva	8.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Marvin Slosman en comparación con los beneficios de InspireMD?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$26m
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	US$3m	US$470k	-US$20m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$697k	US$433k	-US$18m
Sep 30 2022	n/a	n/a	-US$18m
Jun 30 2022	n/a	n/a	-US$17m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$2m	US$410k	-US$15m
Sep 30 2021	n/a	n/a	-US$15m
Jun 30 2021	n/a	n/a	-US$13m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$1m	US$367k	-US$11m

Compensación vs. Mercado: La compensación total de Marvin($USD3.22M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD434.45K).

Compensación vs. Ingresos: La compensación de Marvin ha aumentado mientras la empresa no es rentable.

CEO

Marvin Slosman (60 yo)

4.8yrs

Permanencia

US$3,219,321

Compensación

Mr. Marvin L. Slosman has been President, Chief Executive Officer and Director of InspireMD, Inc. since January 1, 2020. Mr. Slosman served as Chief Operating Officer for MEDCURA Incorporated from May 2019...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Marvin Slosman	President	4.8yrs	US$3.22m	0.025% $ 15.5k
Craig Shore	CFO, Chief Administrative Officer	less than a year	US$1.80m	9.33% $ 5.8m
Shane Gleason	Chief Commercial Officer	1.2yrs	US$1.15m	2.11% $ 1.3m
Andrea Tommasoli	Chief Operating Officer	1.6yrs	US$359.27k	1.97% $ 1.2m
Amir Kohen	Senior Vice President of Finance & HR	less than a year	sin datos	sin datos
Patrick Verta	Executive Vice President of Clinical & Medical Affairs	less than a year	sin datos	0.72% $ 451.6k
Pete Ligotti	Executive VP & GM of North America	less than a year	sin datos	sin datos
Sol Barer	Special Advisor to the Board	no data	US$13.92k	sin datos

1.1yrs

Permanencia media

61.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de II2 no se considera experimentado ( 0.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Marvin Slosman	President	4.8yrs	US$3.22m	0.025% $ 15.5k
Michael Berman	Independent Director	11.7yrs	US$380.25k	1.62% $ 1.0m
Elazer Edelman	Member of Advisory Board	no data	sin datos	sin datos
Thomas Kester	Independent Director	8.1yrs	US$385.25k	1.27% $ 791.6k
Antonio Colombo	Member of Advisory Board	no data	sin datos	sin datos
Alexandre Abizaid	Member of Advisory Board	no data	sin datos	sin datos
Martin B. Leon	Member of Advisory Board	no data	sin datos	sin datos
Eberhart Grube	Member of Advisory Board	no data	sin datos	sin datos
Paul Stuka	Independent Chairman of the Board	13.2yrs	US$574.93k	1.21% $ 755.0k
Kenneth Rosenfield	Chair of Scientific Advisory Board	3.5yrs	sin datos	sin datos
Yaron Almagor	Member of Advisory Board	no data	sin datos	sin datos
Edo Kaluski	Member of Advisory Board	no data	sin datos	sin datos

8.1yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de II2 se considera experimentada (7.8 años de antigüedad promedio).

InspireMD Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

InspireMD, Inc., Annual General Meeting, Jun 10, 2024

Insider recently bought €116k worth of stock

InspireMD, Inc. Announces Management Appointments

InspireMD, Inc., Annual General Meeting, Sep 13, 2023

Insider recently bought €67k worth of stock

Recent updates

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Second quarter 2024 earnings released: US$0.22 loss per share (vs US$0.24 loss in 2Q 2023)

New major risk - Share price stability

InspireMD, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2023)

InspireMD, Inc. to Report Q1, 2024 Results on May 14, 2024

Insufficient new directors

InspireMD, Inc., Annual General Meeting, Jun 10, 2024

Full year 2023 earnings released: US$0.82 loss per share (vs US$2.35 loss in FY 2022)

InspireMD, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Insider recently bought €116k worth of stock

Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption (Ide) Clinical Trial

InspireMD, Inc. to Report Q3, 2023 Results on Nov 06, 2023

InspireMD, Inc. Announces Management Appointments

Second quarter 2023 earnings released: US$0.24 loss per share (vs US$0.59 loss in 2Q 2022)

InspireMD, Inc., Annual General Meeting, Sep 13, 2023

InspireMD, Inc. to Report Q2, 2023 Results on Aug 08, 2023

InspireMD, Inc. Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption Clinical Trial

InspireMD, Inc. announced that it has received $42.169643 million in funding from Marshall Wace LLP, OrbiMed Advisors LLC, Nantahala Capital Management, LLC, Soleus Capital Management, L.P., Velan Inc. and other investors

InspireMD, Inc. to Report Q1, 2023 Results on May 15, 2023

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.53 loss in 3Q 2021)

InspireMD, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Insider recently bought €67k worth of stock

Second quarter 2022 earnings released: US$0.59 loss per share (vs US$0.46 loss in 2Q 2021)

InspireMD, Inc. to Report Q2, 2022 Results on Aug 09, 2022

InspireMD, Inc. Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

InspireMD, Inc., Annual General Meeting, Aug 31, 2022

First quarter 2022 earnings released: US$0.57 loss per share (vs US$0.53 loss in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application

InspireMD, Inc. to Report Q4, 2021 Results on Mar 08, 2022

InspireMD Appoints Adnan Siddiqui as Member of Its Scientific Advisory Board and Strategic Advisor

Insider recently bought €88k worth of stock

Third quarter 2021 earnings released: US$0.53 loss per share (vs US$0.96 loss in 3Q 2020)

Insider recently bought €79k worth of stock

Second quarter 2021 earnings released: US$0.46 loss per share (vs US$2.93 loss in 2Q 2020)

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

First quarter 2021 earnings released: US$0.53 loss per share (vs US$6.42 loss in 1Q 2020)

Full year 2020 earnings released: US$0.47 loss per share (vs US$4.80 loss in FY 2019)

Revenue misses expectations

InspireMD, Inc. to Report Q4, 2020 Results on Mar 09, 2021

InspireMD, Inc. Engages Hart Clinical Consultants to Conduct Clinical Trial for Cguard Carotid Stent System in the United States

InspireMD, Inc. Appoints Chris Metzger as Principal Investigator for CGuard Registration Trial in the United States

New 90-day high: €0.88

InspireMD, Inc. has completed a Composite Units Offering in the amount of $18 million.

InspireMD, Inc. Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China

New 90-day high: €0.64

New 90-day high: €0.50

Revenue beats expectations

Third quarter 2020 earnings released: US$0.064 loss per share

Inspiremd, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing

InspireMD, Inc. to Report Q3, 2020 Results on Nov 09, 2020

InspireMD, Inc. announced that it has received $0.1 million in funding

InspireMD Announces Gary S. Roubin, M.D., Ph.D., to Join Board of Directors

InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives

InspireMD, Inc. to Report Q3, 2019 Results on Nov 12, 2019

New 90-day low: €0.28

InspireMD, Inc.(AMEX:NSPR) dropped from S&P TMI Index

New 90-day low - €0.32

New 90-day low - €0.35

InspireMD Regains Compliance with NYSE Listing Standards

InspireMD, Inc. to Report Q2, 2020 Results on Aug 05, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad